Dr Reddy's Lab launches duloxetine delayed-release capsules

Drug maker Dr Reddy's Laboratories has launched duloxetine delayed-release capsules USP 20 mg, 30 mg and 60 mg in the US market, the company said today.

According to IMS health, Cymbalata (duloxetine delayed- release capsules) brand and generic had US sales of $5.04 billion for the most recent 12 months ending April 2014, Dr Reddy's said in the statement.

The US FDA in December last year approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), for Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Lupin Ltd, Sun Pharma Global FZE, Teva Pharmaceuticals USA and Torrent Pharmaceuticals Ltd to market the drug in various strengths.

Cymbalta (duloxetine) is used to treat major depressive disorder, general anxiety disorder and fibromyalgia.

Common adverse reactions reported by people taking Cymbalta include nausea, dry mouth, drowsiness, fatigue, decreased appetite, increased sweating, and dizziness, FDA had said in the website earlier.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs.

Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs, it had said.